ReviewCureus2026
Gatekeepers of Pain: A Scoping Review on How Nanoparticle Engineering Illuminates Selective Transient Receptor Potential Vanilloid 1 (TRPV1) Targeting.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventional analgesics often provide limited relief for chronic pain and can cause systemic side effects. This scoping review aims to analyze mechanistic and bibliometric trends in nanoparticle-engineered delivery systems designed to selectively modulate transient receptor potential vanilloid 1 (TRPV1) receptors for precision chronic pain therapy; following PRISMA 2018 guidelines, the first 100 top-cited records from the Web of Science (WoS) Core Collection were organized in Microsoft Excel (Microsoft® Corp., Redmond, WA) and BibTeX (Oren Patashnik, Stanford University, Stanford, CA) for bibliometric analysis, with data also being qualitatively synthesized. Citation patterns were concentrated among a few leading researchers and institutions, highlighting the value of aligning with established funding bodies. Advanced polymeric and magnetic nanoparticles demonstrated the ability to cross the blood-brain barrier and selectively modulate TRPV1-mediated pain pathways. Nanoparticles carrying charged capsaicinoids improved bioavailability and reduced neuroinflammation relative to free capsaicin. Dose-dependent effects were consistently observed, as sustained low-dose release produced receptor desensitization and analgesia, while burst or high-dose delivery caused neuronal ablation. Surface-functionalized nanoparticles, particularly those with TRPV1-binding ligands or redox-responsive coatings, enhanced receptor specificity and reduced transient receptor potential ankyrin 1 (TRPA1) co-activation. Rationally engineered nanoparticles optimized for size, charge, ligand density, and release kinetics present a promising avenue for safer, more effective chronic pain therapies. By selectively modulating TRPV1 while mitigating thermoregulatory disruption, researchers can achieve long-lasting analgesia by prioritizing targeting precision to advance sustainable chronic pain treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.